文献速递临床免疫质量管理与危急值

MAGLUMI®他克莫司(CLIA)检测的分析性能及与LC-MS/MS和ARCHITECT(CMIA)检测的比较

MAGLUMI® Tacrolimus (CLIA) assay: analytical performances and comparison with LC-MS/MS and ARCHITECT Tacrolimus (CMIA) assay.
PubMed 文献 · Clin Chem Lab Med · 2025-07-16

该研究评估了基于化学发光免疫分析(CLIA)的MAGLUMI®他克莫司检测的分析性能,并与LC-MS/MS及ARCHITECT他克莫司(CMIA)检测进行比较。结果显示MAGLUMI®检测精密度优异,LoB为0.1 μg/L、LoQ为0.5 μg/L,线性良好(r=0.99990,0.5-50 μg/L),无干扰,且与LC-MS/MS和CMIA检测结果强相关且一致。结论认为MAGLUMI®他克莫司检测性能优异,可作为他克莫司测定的良好替代方法。

要点

  • MAGLUMI®他克莫司(CLIA)检测重复性和批间精密度CV分别为0.55-3.63%和2.18-5.14%。
  • 该检测LoB为0.1 μg/L,LoQ为0.5 μg/L,线性范围0.5-50 μg/L(r=0.99990)。
  • 与LC-MS/MS和ARCHITECT(CMIA)检测结果强相关且一致,无干扰。

核心结论

  • MAGLUMI®他克莫司(CLIA)检测性能优异,与LC-MS/MS和ARCHITECT检测强一致,可作为他克莫司测定的良好替代方法。

研究设计与样本

  • 使用患者全血样本评估MAGLUMI®他克莫司(CLIA)检测的精密度、空白限(LoB)、定量限(LoQ)、检测限(LoD)和线性。
  • 通过向临床样本中引入潜在干扰物评估干扰。
  • 纳入125份患者全血样本和44份加标样本,分析与LC-MS/MS及ARCHITECT他克莫司(CMIA)检测的相关性和一致性。

主要发现

  • 重复性和批间精密度CV分别为0.55-3.63%和2.18-5.14%。
  • LoB为0.1 μg/L,LoQ为0.5 μg/L;LoD验证中所有样本他克莫司浓度均高于LoB。
  • 线性范围为0.5-50 μg/L(r=0.99990),无干扰。
  • 与LC-MS/MS和CMIA检测结果强相关且一致。

关键数值与推荐

  • 重复性CV为0.55-3.63%,批间精密度CV为2.18-5.14%。
  • LoB为0.1 μg/L,LoQ为0.5 μg/L。
  • 线性范围为0.5-50 μg/L,r=0.99990。

临床怎么用

  • MAGLUMI®他克莫司(CLIA)检测可作为他克莫司血药浓度监测的替代方法,尤其适用于需要快速周转的临床实验室。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tacrolimus has been a cornerstone of immunosuppressive therapy over the past two decades. Due to its narrow therapeutic window and pharmacokinetic variability, drug monitoring is vital for enhancing the efficacy and safety during therapy. In the present study, we evaluated the analytical performances of the MAGLUMI® Tacrolimus assay based on chemiluminescent immunoassay (CLIA), and compared with LC-MS/MS and the previously validated ARCHITECT Tacrolimus assay based on chemiluminescent microparticle immunoassay (CMIA). METHODS: We assessed the precision, limit of blank (LoB), limit of quantification (LoQ), limit of detection (LoD) and linearity of the MAGLUMI® Tacrolimus assay using patient whole blood samples. Interference was assessed by introducing potential interferents into clinical samples. We also analyzed the correlation and agreement with the gold standard method (LC-MS/MS) and another previously validated high-performing ARCHITECT Tacrolimus (CMIA) assay by including 125 whole blood samples from patients and 44 spiked samples. RESULTS: MAGLUMI® Tacrolimus (CLIA) assay exhibits superior precision, as coefficients of variation (CVs) for reproducibility and between-run precision were 0.55-3.63 % and 2.18-5.14 %, respectively. The LoB and LoQ were 0.1 μg/L and 0.5 μg/L. All samples in LoD verification had tacrolimus concentrations above LoB. The assay exhibited excellent linearity (r=0.99990, 0.5-50 μg/L) with no interference. Additionally, the results of the MAGLUMI® Tacrolimus (CLIA) assay showed strong correlation and concordance with LC-MS/MS and the CMIA assay. CONCLUSIONS: The MAGLUMI® Tacrolimus (CLIA) assay has excellent performance and strong concordance with LC-MS/MS and the ARCHITECT assay, making it a good alternative for tacrolimus measurement.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Fu M, Chen S, Zheng X, et al. MAGLUMI® Tacrolimus (CLIA) assay: analytical performances and comparison with LC-MS/MS and ARCHITECT Tacrolimus (CMIA) assay. Clin Chem Lab Med. 2025. PMID: 40662389. doi:10.1515/cclm-2025-0181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。